Disease · MONDO_0004822
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Mannitol vs Control: Safety Profile - Sputum Microbiology | 81 of 233 | 81 of 228 | 461 | NCT00669331 | Trial comparisons |
| Mannitol vs Control: Safety Profile - Hematology | 13 of 233 | 5 of 228 | 461 | NCT00669331 | Trial comparisons |
| Mannitol vs Control: serious adverse events | 43 of 233 | 51 of 228 | 461 | NCT00669331 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): deaths from any cause | 1 of 176 | 1 of 197 | 373 | NCT03093974 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): serious adverse events | 31 of 176 | 46 of 197 | 373 | NCT03093974 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): deaths from any cause | 3 of 152 | 2 of 135 | 287 | NCT03460704 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): serious adverse events | 27 of 152 | 17 of 135 | 287 | NCT03460704 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa | 8 of 81 | 5 of 80 | 161 | NCT02088216 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: Adverse Events (AEs) (Elevation of Liver Enzymes) | 3 of 81 | 0 of 80 | 161 | NCT02088216 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: Nature of Sputum (Number of Patients With Yellow Purulent) | 12 of 81 | 31 of 80 | 161 | NCT02088216 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: deaths from any cause | 2 of 81 | 3 of 80 | 161 | NCT02088216 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: serious adverse events | 0 of 81 | 0 of 80 | 161 | NCT02088216 | Trial comparisons |
| Ciprofloxacin Inhale (BAYQ3939) vs Placebo: serious adverse events | 4 of 60 | 6 of 64 | 124 | NCT00930982 | Trial comparisons |
| QBW251 300 mg b.i.d vs Placebo: Number of Participants With Absence of Any Colony-forming Units of Potentially Pathogenic Bacteria Sputum | 0 of 21 | 0 of 21 | 42 | NCT04396366 | Trial comparisons |
| AZD9668 vs Placebo: serious adverse events | 0 of 22 | 0 of 16 | 38 | NCT00769119 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004822/comparisons